NASDAQ:SPRY
ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc.'s revenue fell 5.5% in fiscal 2025 to $84.3M while operating margin fell to −212.9%. Free cash flow was −$171.2M, −203.1% of revenue, and the diluted share count fell 3.7%.Summary generated from ARS Pharmaceuticals, Inc.'s SEC filings. Latest annual report filed Mar 9, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$84.3M
Revenue growth−5.5%
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating margin−212.9%
Net margin−203.3%
ROIC−75.5%
Return on equity−92.3%
Debt / equity0.84
Free cash flow−$171.2M
FCF margin−203.1%
Share count change−3.7%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 6 | 1 | 0 | 89 | 84 |
| Operating income | −19 | −36 | −68 | −3 | −179 |
| Net income | −20 | −35 | −54 | 8 | −171 |
| Free cash flow | −18 | −40 | −59 | 13 | −171 |
Recent filings
- 4Insider transaction report
Oct 5, 2026 - 4Insider transaction report
Sep 2, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 13, 2026 - 8-KResults of operations and financial condition
Aug 13, 2026 - 8-KDirector or officer change
Jul 17, 2026 - 8-KDirector or officer change
Jul 7, 2026 - 8-KResults of a shareholder vote
Jun 25, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 15, 2026